News

Bonumose Announces Key Advisory and Leadership Appointments

Bonumose, Inc. – an enzyme technology company with solutions for sugar reduction and other globally critical industries – is pleased to announce the following appointments.

  • Dr. Andrew Fordyce has accepted a key advisory role with Bonumose. Dr. Fordyce most recently was Executive Vice President and Food & Beverage Divisional Head for Novozymes, a global leader in biological solutions. His experience includes executive management in both functional and business unit organizational structures and he has had a multifaceted career that has covered biotech innovation and business strategy, marketing and business portfolio management, and process engineering and application research. Over Dr. Fordyce’s 27-year career at Novozymes he served multiple management roles including 7 years on the Novozymes’ Executive Leadership Team. Dr. Fordyce is advising Bonumose on multiple aspects of the enzyme value chain, as well as general R&D and business matters.
  • Dr. Katie Whalen. Bonumose has appointed Dr. Whalen, Director of Innovation Delivery, to the additional role of Chief of Staff. Dr. Whalen has a PhD in Biochemistry and prior to Bonumose spent 5 years at Kalsec. In her expanded role, Dr. Whalen is Bonumose’s lead on identifying and filling gaps for organizational capacity development, and also is responsible for ensuring Bonumose maintains a positive culture while scaling its production, global sales, and new product development.
  • Robert Coward. Mr. Coward recently joined Bonumose as Vice President for Finance & Accounting. Mr. Coward was with Xerox (NASDAQ: XRX), an S&P 400 company, for 28 years. Throughout his career Mr. Coward has held increasingly senior leadership roles in finance as well as operations.
  • Ross Bartels. Mr. Bartels, a recent graduate of the University of Virginia School of Law, joined Bonumose as its first in-house legal counsel. Mr. Bartels areas of focus for Bonumose include intellectual property protection, regulatory and administrative law, and general legal matters. Bonumose has over 50 granted patents globally and many more patent applications pending, and also is engaging with food ingredient regulatory bodies globally.

Bonumose is based in Albemarle County, Virginia, and was selected as a Technology Pioneer by the World Economic Forum.

Recent News

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients

08/14/2026

Transforming the finance function in life sciences: Empower scalable growth

Life sciences companies operate in one of the most complex business environments. Long R&D timelines, limited early-stage revenue, and dependence on external funding create a financial landscape where every decision carries strategic weight. In this context, finance is not a back-office function. It is an operational engine that drives whether a company survives, scales, or